Truist Securities Maintains Buy on Abivax, Raises Price Target to $155
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Truist Securities analyst Gregory Renza maintains Abivax (NASDAQ:ABVX) with a Buy and raises the price target from $135 to $155.
Truist Securities analyst Gregory Renza maintains Abivax (NASDAQ:ABVX) with a Buy and raises the price target from $135 to $155.